Key features and details
- Mouse monoclonal [MACIF/629] to CD59
- Suitable for: IHC-P
- Reacts with: Human
- Isotype: IgG1
Product nameAnti-CD59 antibody [MACIF/629]
See all CD59 primary antibodies
DescriptionMouse monoclonal [MACIF/629] to CD59
Tested applicationsSuitable for: IHC-Pmore details
Species reactivityReacts with: Human
Recombinant full length protein corresponding to Human CD59.
Database link: P13987
- IHC-P: Human tongue and tonsil tissues.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.05% Sodium azide
Constituents: PBS, 0.05% BSA
Concentration information loading...
PurityProtein G purified
Purification notesPurified from Bioreactor Concentrate.
Light chain typekappa
Our Abpromise guarantee covers the use of ab234013 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 1 - 2 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Primary incubation for 30 minutes at room temperature.
FunctionPotent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.
The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes.
Involvement in diseaseDefects in CD59 are the cause of CD59 deficiency (CD59D) [MIM:612300].
Sequence similaritiesContains 1 UPAR/Ly6 domain.
modificationsN- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid, but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid, mannose and glucosamine Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants.
Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes.
Cellular localizationCell membrane. Secreted. Soluble form found in a number of tissues.
- Information by UniProt
- 16.3A5 antibody
- 1F5 antibody
- 1F5 antigen antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab234013 has not yet been referenced specifically in any publications.